Century Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 165
- Market Cap
- -
- Website
- http://www.centurytx.com
- Introduction
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.
Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants with Refractory B cell-mediated Autoimmune Diseases
- Conditions
- systemic lupus erythematosus [SLE]/lupus nephritis [LN], idiopathic inflammatory myopathy [IIM], and diffuse cutaneous systemic sclerosis [DcSSc]
- Interventions
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Century Therapeutics Inc.
- Target Recruit Count
- 16
- Registration Number
- 2024-518797-13-00
- Locations
- 🇩🇪
Johannes Wesling Klinikum Minden, Minden, Germany
🇮🇹IRCCS Ospedale Policlinico San Martino, Genoa, Italy
🇮🇹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
- Conditions
- Hematological MalignancySolid Tumor Malignancy
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Century Therapeutics, Inc.
- Target Recruit Count
- 375
- Registration Number
- NCT05768269
- Locations
- 🇺🇸
University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies
- Conditions
- Aggressive Non-Hodgkin LymphomaIndolent Non-Hodgkin LymphomaR/R CD19-Positive B-Cell Malignancies
- Interventions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Century Therapeutics, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05336409
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California San Diego, Moores Cancer Center, San Diego, California, United States
News
uBriGene Launches GMP-Compliant iPSC Banks to Accelerate Cell Therapy Development
uBriGene Biosciences has launched fully characterized, ready-to-use induced pluripotent stem cell (iPSC) banks developed using proprietary RNA-LNP reprogramming technology to support clinical applications worldwide.
Cellistic Launches Immune-Cloaked iPSC Cell Lines to Accelerate Cell Therapy Development
Cellistic has introduced Allo Chassis™, ready-to-use iPSC cell lines derived from CD34+ and CD4+ T-cells with HLA class I and II deletions, enabling immune-cloaked allogeneic cell therapies.
Gameto's Fertilo Receives FDA Clearance for Phase 3 iPSC Fertility Trial
Gameto's Fertilo, an iPSC-based therapy, has received FDA IND clearance for a Phase III trial, marking a significant advancement in reproductive medicine.
Evotec Receives $2.5M Gates Foundation Grant for iPSC-Based Teratogenicity Platform
Evotec has joined the Bill & Melinda Gates Foundation's Global Health Discovery Collaboratory (GHDC) after receiving a $2.5 million grant to support its innovative iPSC-derived teratogenicity platform.